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Abstract
Objective and design: YKL-40 is involved in inflammation and endothelial dysfunction, and is increased in
patients with type 1 diabetes, with an independent association between increasing YKL-40 levels and increasing
levels of albuminuria. YKL-40 is associated with atherosclerosis and an increased cardiovascular mortality in the
general population. In the present study YKL-40 levels were examined in patients with type 2 diabetes (T2D) with
increasing levels of albuminuria, known to be associated with an increased risk of cardiovascular disease.
Materials and methods: One-hundred-five patients with T2D were examined: 49 with normoalbuminuria (N, U-
albumin/creatinine < 2.5 mg/mmol), 35 with persistent microalbuminuria (MA, 2.5-25 mg/mmol) and 21 with
persistent macroalbuminuria/diabetic nephropathy (DN, > 25 mg/mmol). The control group consisted of 20 healthy
individuals (C). Groups were matched according to age, gender and known duration of diabetes.
Results: Median levels (interquartile range) of serum YKL-40 were significantly higher in N and MA vs. C (86 (55-
137) ng/ml and 84 (71-147) ng/ml, respectively vs. 41 (33-55) ng/ml, p < 0.01) and even higher in patients with DN
(120 (83-220) ng/ml, p < 0.001 for all comparisons). YKL-40 levels correlated with urinary albumin/creatinine-ratio in
the total group of participants (r = 0.41, p < 0.001). Significant intercorrelations of YKL-40 were found with age,
duration of diabetes, systolic blood pressure, lipid levels, HbA1c and HOMA-IR. After adjustment for significant
covariates, albuminuria was significantly associated with YKL-40 levels (r = 0.32, p = 0.006).
Conclusions: YKL-40 levels are elevated in patients with T2D with an independent association between increasing
YKL-40 levels and increasing levels of albuminuria. The study suggests a role of YKL-40 in the progressing vascular
complications in patients with T2D.
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Introduction
Albuminuria is a well-established independent predictor
for diabetic nephropathy and is also a strong predictor
for cardiovascular morbidity and mortality in both
patients with type 1 (T1D) and type 2 diabetes (T2D)
[1-4]. The exact mechanisms between albuminuria and
cardiovascular disease are still unclear, but it is sug-
gested that increasing levels of albuminuria reflect vas-
cular damage in the kidneys as part of a systemic
endothelial dysfunction, which is the initial step in
atherogenesis [5]. Individuals with diabetes have in
general a 2- to 4-fold increased risk of subsequent cardi-
ovascular disease (CVD)[6].
YKL-40 is a glycoprotein involved in inflammation
and endothelial dysfunction. It is a growth factor for
various cell types and has an important role in extracel-
lular matrix remodeling and angiogenesis [7,8]. In the
last few years, several clinical studies have described ele-
vated YKL-40 levels in several cardiovascular conditions,
as well as described an association between YKL-40 and
mortality. YKL-40 has been found to be associated with
all-cause as well as cardiovascular mortality in both
patients with stable ischemic heart disease (IHD) [9]
and in the general population above 50 years of age
without known diabetes or IHD [10]. YKL-40 levels are
elevated both in patients with T1D and T2D known to
be at high risk for the development of cardiovascular
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levels of YKL-40 are seen with increasing levels of albu-
minuria, suggesting that YKL-40 might be able to be
used as an early marker of CVD [11].
The objective of the present study was to evaluate
serum YKL-40 in patients with T2D and with increasing
levels of albuminuria.
Materials and methods
Study population
One-hundred-five patients with T2D were examined: 49
with normoalbuminuria (N, U-albumin/creatinine < 2.5
mg/mmol), 35 with persistent microalbuminuria (MA,
2.5-25 mg/mmol) and 21 with persistent macroalbumi-
nuria/diabetic nephropathy (DN, > 25 mg/mmol). The
control group consisted of 20 healthy individuals (C).
Groups were matched according to age, gender and
known duration of diabetes.
Measurements
Plasma samples were taken as part of the first routine
visit (inclusion) in the morning after an overnight fast
a n dw e r es t o r e da t-8 0 ° Cu n t i la n a l y s i s .B e s i d er o u t i n e
analyses, analyses of serum YKL-40 were measured
using ELISA method (Quidel, USA). Measuring range
was 20-300 ng/ml, with intra- and interassay coefficients
of variation of 5.8% and 6.0%. Glomerular filtration rate
(GFR) was estimated using the 4 variable Modification
of Diet in Renal Disease GFR formula (age, gender, race,
serum creatinine) http://mdrd.com/. Insulin resistance
was estimated using the HOMA model http://www.dtu.
ox.ac.uk/homacalculator/index.php. Urinary albumin
was measured by immunoturbidimetry on a Cobas Bioa-
nalyzer (Roche Products, Switzerland) from early morn-
ing spot urine collections. Lower detection limit was 1
mg/l, coefficients variations < 4.0%. Urinary creatinine
was measured by a Jaffé reaction rate, using a kinetic
principle to eliminate pseudocreatinines. Urinary albu-
min excretion was determined as UACR. The degree of
albuminuria was confirmed by at least 2 consecutive
tests. Diabetic retinopathy was assessed in most patients
by fundus photography after pupillary dilatation and
graded as nil, simplex or proliferative retinopathy.
The study was approved by the Danish Data Protec-
tion Agency (id. 30122009.HEH.O.JF) and the local
ethics committee of Copenhagen (KA 03065) and inves-
tigations conformed to the principles of The Helsinki
Declaration.
Statistical analyses
Following a test of statistical normality, data values are
presented as mean ± SD or as median and interquartile
range (IQR). For continuous variables, comparisons
between the group of patients with T2D and the group
of control subjects were performed with One-Way
ANOVA. Mann-Whitney test was used if Levene’st e s t
for equality of variance was significant, or if a variable
exhibited a clear non-Gaussian distribution. If data had
a non-Gaussian distribution data were logarithmically
transformed. Analyses of intercorrelations and associa-
tions were performed using univariate and multivariate
linear regression analysis. The c2-test was used for cate-
gorical variables.
P values were two-sided, and p < 0.05 was considered
statistically significant. All analyses were made with the
statistical software package SPSS (version 11.5 SPSS;
Chicago, IL).
Results
Clinical data for the control group and the T2D patients
with different levels of albuminuria is shown in Table 1.
The groups were closely matched according to age, gen-
der and duration of diabetes. YKL-40 levels according to
level of albuminuria are illustrated in Figure 1.
Median YKL-40 levels were significantly different
between groups with increasing YKL-40 levels with
increasing levels of albuminuria (p < 0.001). We found
no difference in eGFR between the different groups (p =
0.61). We did find a significant difference in UACR
between the different groups (p < 0.001), even though
most of the patients had UACR levels already reduced
by antihypertensive medication, which was not stopped
when spot urine samples were collected for the study.
There was a significant difference in use of antihyper-
tensive drugs between the groups (p < 0.001), with as
expected more patients treated in the micro- and
macroalbuminuric groups.
We found no significant difference in systolic or dia-
stolic blood pressure between the groups for all compar-
isons or comparisons of the diabetic groups. We did
find significant differences in cholesterol and HbA1c
levels (p < 0.001) between all groups due to differences
between controls and the diabetic groups in total. No
significant differences in cholesterol or HbA1c were
found the diabetic groups in between.
Simple and multiple regression analyses showed corre-
lation of YKL-40 with UACR in the total group of parti-
cipants (r = 0.41, p < 0.001) (Table 2, Figure 2).
Significant intercorrelations of YKL-40 were also found
with age, HOMA-IR, HbA1c, total cholesterol, LDL-
cholesterol, triglycerides, duration of diabetes, and systo-
lic blood pressure (0.001 < p < 0.047) (Table 2).
In a multiple regression model adjusting for the signif-
i c a n tc o v a r i a t e s( U A C R ,a g e ,H O M A - I R ,H b A 1 c ,t r i g l y -
cerides, systolic blood pressure, duration of diabetes,
total cholesterol and LDL-cholesterol), albuminuria was
still found to be significantly associated with YKL-40
levels (r = 0,32, p = 0.006). Moreover, significant
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0.52, p = 0.024) and LDL-cholesterol (r = -0.53, p =
0.021).
UACR was significantly associated with YKL-40, BMI,
HbA1c and systolic blood pressure (0.001 < p < 0.02). A
multiple regression analyses adjusted for significant cov-
ariates demonstrated that YKL-40 was associated with
albuminuria (r = 0.42, p < 0.001).
More patients with T2D were treated with statins,
when compared to the control subjects (p < 0.001),
but there were no differences in the number of T2D
treated between the groups. No differences were seen
in levels of YKL-40 in the whole group of T2D patient
treated with statins when compared to non-treated
patients (p = 0.18), nor in the individual groups (0.1 <
p < 0.9).
At baseline, only a limited number of subjects had a
history of myocardial infarction, stroke or symptoms of
intermittent claudicatio. No differences in YKL-40 levels
were found in patients with a history of CVD (any),
when compared to patients without these macrovascular
complications (p = 0.47). However, more patients with
macroalbuminuria had CVD (c
2 =8 . 6 ,p=0 . 0 3 6 ) .
Patients with retinopathy had significantly higher levels
of YKL-40 (p = 0.01), only due to differences between
normoalbuminuric and microalbuminuric patients (p =
0.021). More patients with albuminuria had retinopathy
(c
2 = 23.6, p = 0.001).
Discussion
Micro- and macrovascular complications are known to
decrease the quality of life as well as shorten the life
Table 1 Clinical data of control group and the type 2 diabetic patients differentiated according to level of albuminuria
Control group Normoalbuminuria Microalbuminuria Macroalbuminuria p value
N, total 20 49 35 21
Male (%) 60.4 44.8 34.3 42.3 0.24
Age (years) 57.1 (7.2) 61.3 (12.0) 60.1 (11.7) 64 (13.1) 0.23
DM duration (years) - 5.0 (0.3-10.0) 6.0 (0.2-10.0) 5.5 (3.3-9.8) 0.65
BMI (kg/m
2) 28.9 (2.9) 29.9 (5.7) 33.9 (7.4) 30.9 (5.7) 0.02
Smoking 2 (10.0%) 19 (38.7%) 19 (49.0%) 8 (38.1%) 0.25
Use of antihypertensiva 0 31 (63.2%) 28 (80.0%) 19(90.5%) < 0.001
Use of statins 1 (5.0%) 33 (67.3%) 21 (60.0%) 13 (61.9%) < 0.001
Use of aspirin 1 (5.0%) 24 (49.0%) 10 (30.0%) 12 (57%) < 0.001
Use of metformin - 30 (61.2%) 16 (45.7%) 14 (66.7%) < 0.001
Use of SU - 20 (40.8%) 12 (34.2%) 8 (38.1%) 0.008
Use of Insulin - 7 (14.2%) 6 (17.1%) 5 (23.8%) 0.14
YKL-40 (ng/ml) * 41 (33-55) 86 (55-137) 84 (71-147) 120 (83-220) < 0.001
HbA1c (%) ** 5.6 (0.3) 8.6 (2.1) 8.0 (2.0) 7.9 (1.8) < 0.001
Creatinine (μmol/l) ** 85 (76-94) 75 (65-93) 80 (65-91) 106 (66-121) 0.45
UACR (mg/mmol) *† 0.57 (0.34-1.53) 0.68 (0.39-1.23) 6.65 (4.06-11.47) 49.3 (36.9-102.9) < 0.001
eGFR (ml/min/1.73 m
2) ** 78.2 (25.7) 81.6 (21.9) 83.8 (24.3) 73.4 (32.3) 0.61
Cholesterol (mmol/l) 5.6 (0.9) 4.5 (1.2) 4.6 (1.0) 4.6 (1.1) 0.001
Systolic BP (mmHg) ** 142 (17) 137 (18) 140 (16) 145 (17) 0.23
Diastolic BP (mmHg) ** 85 (12) 81 (8) 83 (11) 83 (11) 0.34
History of:
CVD (all) 0 11 (22.4%) 5 (14.3%) 7 (33.3%) 0.03
Myocardial infarction 0 5 (10.2%) 3 (8.6%) 1 (4.7%) 0.49
Stroke 0 5 (10.2%) 2 (5.7%) 4 (19.0%) 0.11
PAOD 0 3 (6.1%) 1 (2.8%) 3 (14.3%) 0.13
Retinopathy:
- none - 36 (73.5%) 30 (85.7%) 10 (47.6%) 0.002
- simplex - 2 (4.1%) 2 (5.7%) 3 (14.2%) 0.002
- proliferative - 0 0 3 (14.2%) 0.002
Presented as numbers (%) where not specified. * Median (IQR). ** Mean (SD). † Most of the patients had UACR levels reduced by antihypertensive medication
which was not stopped when spot urine samples were collected for the study.
HbA1c, hemoglobin A1c; UACR, urinary albumin/creatinine ratio; eGFR, estimated glomerular filtration rate (MDRD); BP, blood pressure; PAOD, peripheral arterial
occlusive disease.
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intensive research in the pathological mechanisms
resulting in improved and intensified treatment of dia-
betes and its vascular risk factors and complications,
there is still a need for supplementary risk markers to
understand the pathogenesis and predict the develop-
ment of micro- and macrovascular disease.
We evaluated levels of YKL-40, a marker of inflamma-
tion and endothelial dysfunction, in patients with T2D. We
found significant elevated YKL-40 levels in patients with
T2D compared to healthy control subjects, and significant
increased YKL-40 levels with increasing levels of albumi-
nuria. This finding is in accordance with previous studies
showing that chronic low-grade inflammation is associated
with the occurrence and progression of microalbuminuria
[13], and that both micro- and macroalbuminuria are
accompanied by increased levels of a variety of markers of
endothelial dysfunction [14]. Our findings are also in
accordance with previous studies showing that YKL-40
levels are elevated in both T2D and T1D patients, when
compared to control subjects, and for T1D patients with
microvascular disease [10-12,15]. Rathcke et al found that
YKL-40 levels were elevated in patients with T1D and
increased with levels of albuminuria, and that YKL-40
levels were independently associated with increasing levels
of albuminuria after adjustment for significant covariates
[12], comparable to the results of this study of T2D
patients and control subjects.
Similar to our findings, 2 recent studies have shown
significant elevation of YKL-40 in T2D patients with
albuminuria [16,17]. In a brief report from Japan,
increased YKL-40 levels were found in normal weight or
slightly overweight patients with T2D with different
levels of albuminuria [17]. Regression analyses demon-
strated, as in our study, an association between YKL-40
and albuminuria, and that serum YKL-40 was a determi-
nant of albuminuria independently of conventional risk
factors [17]. No control group was included in the Japa-
nese study and the duration of diabetes was approxi-
mately 16 years, in the present study 5.5 years, which
may influence YKL-40 levels as seen in our study, and
nothing was mentioned about medication and CVD. In
a study from Austria, comparable results were found,
but again no control group was included and the dura-
tion of diabetes was 11-14 years, and the percentage of
patients with any CVD was between 75-82%, in our
study 11-33%, implying more advanced CVD in the
T2D patients from Austria [16].
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Figure 1 Median levels (interquartile range) of serum YKL-40
were significantly higher in N and MA vs. C (86 (55-137) ng/ml
and 84 (71-147) ng/ml, respectively vs. 41 (33-55) ng/ml, p <
0.01) and even higher in patients with DN (120 (83-220) ng/ml,
p < 0.001 for all comparisons).
Table 2 Intercorrelations of YKL-40
Correlation coefficient P
UACR 0.41 < 0.001
Age 0.32 < 0.001
HOMA-IR 0.31 0.004
HbA1c 0.28 0.004
Triglycerides 0.23 0.011
Systolic blood pressure 0.20 0.029
Duration of diabetes 0.20 0.045
Total cholesterol -0.25 0.006
LDL-cholesterol -0.20 0.047
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0,0 1,0 2,0
LogUACR
1,2
1,6
2,0
2,4
2,8
L
o
g
Y
K
L
-
4
0
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$$
$
$
$
$
$
$
$
$
$ $
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$ $
$
$
$
$
$
$
$
$
$
$
$
$
$ $
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$
$ $
$
$ $
$
$
$ $
$
Figure 2 Association between log-transformed UACR and YKL-
40 levels (r = 0.41, p < 0.0001).
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nuria in both T1D and T2D could reflect common
determinants, such as inflammation, or a causal link
where inflammation leads to increase in YKL-40, and
subsequent generalized vascular damage reflected by
albuminuria. YKL-40 is excreted by the kidney and this
may affect the predictive ability of the biomarker in
patients with impaired kidney function. Not surprisingly
we found a significant correlation between YKL-40 and
UACR, but we did not find that increasing YKL-40
levels were predicted by a decline in eGFR. Despite the
correlation between YKL-40 and UACR, we found a sig-
nificant association between YKL-40 levels and level of
albuminuria after adjustment for significant covariates,
implicating increasing albuminuria with increasing YKL-
40 levels.
In a previous study we found an association between
YKL-40 and an increased cardiovascular (CV) mortality
rate in an elderly part of the general population without
diabetes and CVD, after adjustment for known CVD
risk factors and markers [10]. YKL-40 and UACR were
independent markers of CVD mortality with only weak
intercorrelation and in accordance with the studies on
low-grade albuminuria and risk of CVD, YKL-40 and
low-grade albuminuria had a synergistic prediction of
CVD mortality. Other studies have supported the asso-
ciation between YKL-40 and CVD morbidity and mor-
tality, showing that YKL-40 levels are associated with
the presence and extent of coronary artery disease as
assessed by coronary angiography [18]. Moreover YKL-
40 levels have been found to be elevated in patients
with myocardial infarction [19].
It has been demonstrated that statins, through their
capacity to inhibit inflammation, can reduce the
increased inflammatory activities seen with progression
of atherosclerosis, and this is correlated with the reduc-
tion in calcification [20]. In the present study we found
that significantly more T2D patients were treated with
statins, and no differences were found between the dia-
betic groups. Because of the higher levels of YKL-40
seen in T2D patients, we cannot exclude that statin
treatment has influenced the levels of YKL-40, as seen
in a previous study demonstrating reduced YKL-40 in
statin compared to non-statin treated atherosclerotic
patients [21]. However, since statin treatment reduces
inflammation and can ameliorate the calcification
response in the vessel wall, higher YKL-40 levels would
be expected had the patients been without statin treat-
ment. However, no differences were found in levels of
YKL-40 between statin treated and non-treated patients.
Vascular endothelial dysfunction is an important fac-
tor in the pathogenesis of diabetic micro- and maroan-
giopathy [14]. YKL-40 promotes chemotaxis, cell
attachment, spreading, and migration of vascular
endothelial cells, suggesting that YKL-40 promotes the
process of atherosclerotic plaque formation, in which
vascular smooth muscle cells (VSMCs) are induced to
m i g r a t et h r o u g ht h ei n t i m ai nr e s p o n s et oe x o g e n o u s
signals [7]. YKL-40 also participates in the modulation
of vascular endothelial cell morphology by promoting
the formation of branching tubules, indicating a role of
YKL-40 in angiogenesis by stimulating the migration
and reorganization of VSMCs [7]. Moreover, YKL-40 is
produced and secreted by monocytes during differentia-
tion to macrophages but is also secreted by activated
macrophages, and YKL-40 protein expression is found
in vivo in both macrophages and VSMCs in the athero-
sclerotic plaque [8]. In accordance with this finding,
both T1D and T2D patients have been found to have
increased monocytic activity characterized by increased
monocytic release of proinflammatory cytokines and
reactive oxygen species, which is accentuated in T1D
patients with microvascular complications [22]. There-
fore, it seems that YKL-40 participates in monocyte dif-
ferentiation and macrophage activation as part of the
endothelial dysfunction and the processes during early
stages of atherosclerosis [8]. YKL-40 seems to be of
pathogenic importance in the low-grade inflammation
that precedes the development of CVD.
YKL-40 also seems to promote tumor angiogenesis
in colon and breast cancer [23], an effect that could
point to a common pathway for several disease pro-
cesses, where YKL-40 is expressed in monocytes, sti-
mulates monocyte maturation and differentiation to
macrophages, and stimulates macrophage activation
and promotes angiogenesis. This cascade can be identi-
fied in the pathology of atherosclerosis, diabetic com-
plications and cancers. However, it still remains to be
elucidated whether YKL-40 is a biomarker of general
inflammation or is more directly involved in specific
disease processes.
There are limitations of the present study. We have
performed a cross-sectional analysis of YKL-40 levels in
relation to albuminuria in patients with T2D; however
long-time studies are needed to clarify whether an
increase in YKL-40 levels in both T1D and T2D patients
is a consequence of a general progressing atherosclerotic
disease, or whether YKL-40 can predict or contribute to
microvascular and macrovascular disease in these
patients. Moreover, in the present study no other mar-
kers of endothelial dysfunction and inflammation were
investigated, e.g. high-sensitive C-reactive protein
(hsCRP). But in contrast to most inflammatory markers,
YKL-40 is locally produced at the site of inflammation
[12,24] and previous studies have either not found or
have found only a weak correlation with C-reactive pro-
tein [10,12]. Perception of YKL-40 as an early marker
[10,24] indicates, that YKL-40 could possibly correlate
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dysfunction.
In conclusion, YKL-40 levels are elevated in patients
with T2D with an independent association between
increasing YKL-40 levels and increasing levels of albu-
minuria after adjustment for UACR, age and other sig-
nificant covariates. A role of YKL-40 in the gradually
progressing vascular complications in patients with dia-
betes is suggested, with YKL-40 being a possible early
marker of the widespread atherosclerotic complications
in diabetic patients.
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